• 1
    Sundaram M, Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) 2010; 7: 35.
  • 2
    Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. HEPATOLOGY 2009; 50: 772-780.
  • 3
    Minehira K, Young SG, Villanueva CJ, Yetukuri L, Oresic M, Hellerstein MK, et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res 2008; 49: 2038-2044.
  • 4
    Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. HEPATOLOGY 2010; 51: 679-689.
  • 5
    Fabbrini E, deHaseth D, Deivanayagam S, Mohammed BS, Vitola BE, Klein S. Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity (Silver Spring) 2009; 17: 25-29.
  • 6
    Borchardt RA, Davis RA. Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion. J Biol Chem 1987; 262: 16394-16402.
  • 7
    Dixon JL, Furukawa S, Ginsberg HN. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem 1991; 266: 5080-5086.
  • 8
    Gibbons GF, Khurana R, Odwell A, Seelaender MC. Lipid balance in HepG2 cells: active synthesis and impaired mobilization. J Lipid Res 1994; 35: 1801-1808.
  • 9
    Wiggins D, Gibbons GF. The lipolysis/esterification cycle of hepatic triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas. Biochem J 1992; 284: 457-462.
  • 10
    Gilham D, Ho S, Rasouli M, Martres P, Vance DE, Lehner R. Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion. FASEB J 2003; 17: 1685-1687.
  • 11
    Yang LY, Kuksis A, Myher JJ, Steiner G. Contribution of de novo fatty acid synthesis to very low density lipoprotein triacylglycerols: evidence from mass isotopomer distribution analysis of fatty acids synthesized from [2H6]ethanol. J Lipid Res 1996; 36: 125-136.
  • 12
    Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003; 44: 22-32.
  • 13
    Benoist F, Grand-Perret T. Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein. Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein. J Biol Chem 1997; 272: 20435-20442.
  • 14
    Ohsaki Y, Cheng J, Fujita A, Tokumoto T, Fujimoto T. Cytoplasmic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B. Mol Biol Cell 2006; 17: 2674-2683.
  • 15
    Su Q, Tsai J, Xu E, Qiu W, Bereczki E, Santha M, et al. Apolipoprotein B100 acts as a molecular link between lipid-induced endoplasmic reticulum stress and hepatic insulin resistance. HEPATOLOGY 2009; 50: 77-84.
  • 16
    Gentile CL, Pagliassotti MJ. The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease. Curr Opin Investig Drugs 2008; 9: 1084-1088.
  • 17
    Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest 2008; 118: 316-332.
  • 18
    Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem 1988; 263: 2998-3004.
  • 19
    Jacobs RL, Devlin C, Tabas I, Vance DE. Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins. J Biol Chem 2004; 279: 47402-47410.
  • 20
    Noga AA, Zhao Y, Vance DE. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem 2002; 277: 42358-42365.
  • 21
    Cabrero C, Duce AM, Ortiz P, Alemany S, Mato JM. Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. HEPATOLOGY 1988; 8: 1530-1534.
  • 22
    Duce AM, Ortiz P, Cabrero C, Mato JM. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. HEPATOLOGY 1988; 8: 65-68.
  • 23
    Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. HEPATOLOGY 2007; 45: 1306-1312.
  • 24
    Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989; 24: 407-415.
  • 25
    Lu SC, Alvarez L, Huang ZZ, Chen L, An W, Corrales FJ, et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci U S A 2001; 98: 5560-5565.
  • 26
    Tomasi ML, Ramani K, Lopitz-Otsoa F, Rodriguez MS, Li TW, Ko K, et al. S-adenosylmethionine regulates dual-specificity mitogen-activated protein kinase phosphatase expression in mouse and human hepatocytes. HEPATOLOGY 2010; 51: 2152-2161.
  • 27
    Ruiz JI, Ochoa B. Quantification in the subnanomolar range of phospholipids and neutral lipids by monodimensional thin-layer chromatography and image analysis. J Lipid Res 1997; 38: 1482-1489.
  • 28
    Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
  • 29
    Cano A, Ciaffoni F, Safwat GM, Aspichueta P, Ochoa B, Bravo E, et al. Hepatic VLDL assembly is disturbed in a rat model of nonalcoholic fatty liver disease: is there a role for dietary coenzyme Q? J Appl Physiol 2009; 107: 707-717.
  • 30
    Cristobal S, Ochoa B, Fresnedo O. Purification and properties of a cholesteryl ester hydrolase from rat liver microsomes. J Lipid Res 1999; 40: 715-725.
  • 31
    Dolinsky VW, Douglas DN, Lehner R, Vance DE. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J 2004; 378: 967-974.
  • 32
    Ridgway ND, Vance DE. Phosphatidylethanolamine N-methyltransferase from rat liver. Methods Enzymol 1992; 209: 366-374.
  • 33
    Bartolomé N, Aspichueta P, Martínez MJ, Vázquez-Chantada M, Martínez-Chantar ML, Ochoa B, et al. Biphasic adaptative responses in VLDL metabolism and lipoprotein homeostasis during Gram-negative endotoxemia. Innate Immun 2010; doi:10.1177/1753425910390722.
  • 34
    Kharbanda KK, Todero SL, Ward BW, Cannella JJ 3rd, Tuma DJ. Betaine administration corrects ethanol-induced defective VLDL secretion. Mol Cell Biochem 2009; 327: 75-78.
  • 35
    Kharbanda KK, Mailliard ME, Baldwin CR, Beckenhauer HC, Sorrell MF, Tuma DJ. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol 2007; 46: 314-321.
  • 36
    Mato JM, Martínez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu Rev Nutr 2008; 28: 273-293.
  • 37
    Fast DG, Vance DE. Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited: evidence for a novel mechanism that regulates VLDL secretion. Biochim Biophys Acta 1995; 1258: 159-168.
  • 38
    Gibbons GF, Wiggins D, Brown AM, Hebbachi AM. Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc Trans 2004; 32: 59-64.
  • 39
    Vázquez-Chantada M, Ariz U, Varela-Rey M, Embade N, Martínez-Lopez N, Fernández-Ramos D, et al. Evidence for LKB1/AMP-activated protein kinase/endothelial nitric oxide synthase cascade regulated by hepatocyte growth factor, S-adenosylmethionine, and nitric oxide in hepatocyte proliferation. HEPATOLOGY 2009; 49: 608-617.
  • 40
    Rencurel F, Foretz M, Kaufmann MR, Stroka D, Looser R, Leclerc I, et al. Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol 2006; 70: 1925-1934.
  • 41
    Aspichueta P, Pérez S, Ochoa B, Fresnedo O. Endotoxin promotes preferential periportal upregulation of VLDL secretion in the rat liver. J Lipid Res 2005; 46: 1017-1026.
  • 42
    Ko K, Yang H, Noureddin M, Iglesia-Ara A, Xia M, Wagner C, et al. Changes in S-adenosylmethionine and GSH homeostasis during endotoxemia in mice. Lab Invest 2008; 88: 1121-1129.
  • 43
    Pan M, Maitin V, Parathath S, Andreo U, Lin SX, St Germain C, et al. Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control. Proc Natl Acad Sci U S A 2008; 105: 5862-5867.
  • 44
    Zhong S, Magnolo AL, Sundaram M, Zhou H, Yao EF, Di Leo E, et al. Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B. J Biol Chem 2010; 285: 6453-6464.